Literature DB >> 26583302

Tavaborole topical solution, 5% for the treatment of toenail onychomycosis.

L T Zane1, J Plattner2, S Chanda2, D Coronado2, T Merchant2, M R K Alley2, A K Gupta3.   

Abstract

Tavaborole topical solution, 5% (tavaborole) is a novel, boron-based, antifungal pharmaceutical agent indicated for treatment of toenail onychomycosis due to the dermatophytes Trichophyton rubrum or Trichophyton mentagrophytes. In preclinical studies, tavaborole effectively penetrated through full-thickness, non-diseased cadaver fingernails, including those with up to four layers of nail polish. Limited systemic absorption was observed following topical application of tavaborole. In phase III clinical trials involving patients with distal subungual onychomycosis affecting 20-60% of a target great toenail, significantly more patients treated with tavaborole versus vehicle achieved completely clear nail with negative mycology following daily application for 48 weeks. Treatment-emergent adverse events reported by at least 1% of patients treated with tavaborole and at a greater frequency versus vehicle included ingrown toenail, exfoliation, erythema and dermatitis. Treatment discontinuations were uncommon. Results from preclinical studies and phase III clinical trials establish tavaborole as a safe and efficacious treatment for toenail onychomycosis. Copyright 2015 Prous Science, S.A.U. or its licensors. All rights reserved.

Entities:  

Keywords:  AN2690; Antifungal agents; Onychomycosis; Tavaborole; Trichophyton rubrum

Mesh:

Substances:

Year:  2015        PMID: 26583302     DOI: 10.1358/dot.2015.51.10.2401004

Source DB:  PubMed          Journal:  Drugs Today (Barc)        ISSN: 1699-3993            Impact factor:   2.245


  1 in total

1.  Efficacy Coefficients Determined Using Nail Permeability and Antifungal Activity in Keratin-Containing Media Are Useful for Predicting Clinical Efficacies of Topical Drugs for Onychomycosis.

Authors:  Yoshiki Matsuda; Keita Sugiura; Takashi Hashimoto; Akane Ueda; Yoshihiro Konno; Yoshiyuki Tatsumi
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.